Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $950.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by JPMorgan Chase & Co. from $900.00 to $950.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Leerink Partners upped their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. Finally, Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target on the stock in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $817.92.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $739.57 on Tuesday. The company has a market cap of $76.15 billion, a price-to-earnings ratio of 18.28, a PEG ratio of 1.39 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock’s fifty day moving average price is $791.31 and its 200 day moving average price is $720.49. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the company earned $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 46.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,946 shares of company stock worth $3,302,458 over the last 90 days. 6.97% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Arjuna Capital increased its holdings in shares of Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares during the period. MCF Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Boyd Watterson Asset Management LLC OH grew its position in Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 15 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 15 shares during the period. Finally, Aaron Wealth Advisors LLC increased its stake in Regeneron Pharmaceuticals by 1.5% in the 1st quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company’s stock valued at $851,000 after buying an additional 16 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts raised price targets. Royal Bank of Canada lifted its target from $737 to $810 while maintaining a “sector perform” rating. Truist also raised its target to $780 and kept a “buy” rating, suggesting potential upside based on current valuation. Analyst price-target report
• Positive Sentiment: Rare-disease pipeline advanced. Regeneron announced a new Phase 3 evaluation of garetosmab in a pediatric rare-disease program. Progress into a late-stage trial could create an additional long-term growth opportunity, although the study remains subject to clinical and regulatory risks. Garetosmab Phase 3 study
• Positive Sentiment: Oncology collaboration could broaden strategic opportunities. Biohaven is working with Regeneron to test BHV-1530 with Libtayo in solid tumors, adding to an existing supply agreement involving Biohaven’s BHV-1510 program. The collaboration may support Regeneron’s oncology presence if the programs produce positive results. Biohaven oncology collaboration
• Neutral Sentiment: Valuation looks comparatively attractive. Regeneron trades at roughly 17.6 times earnings versus about 21.5 times for the median S&P 500 company. The discount could appeal to value-oriented investors, but it may also reflect concerns about future growth or business risks. Regeneron valuation analysis
• Negative Sentiment: Analyst conviction remains limited. Morgan Stanley raised its target to $779 but retained an “equal weight” rating, while RBC’s “sector perform” stance signals neither a clear bullish nor bearish view. The mixed ratings may be restraining the stock despite higher targets.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.